Harvest Health: Second Quarter Consensus Estimates
Harvest Health and Recreation (CSE: HARV) announced that they will be reporting their second quarter financials after the market closes on August 10.
Analysts have a consensus C$7 12-month price target on the company, via a total of 5 analysts, with one analyst having a strong buy rating, and the other 4 analysts having buy ratings. The street high comes from Alliance Global Partners with a C$9.50 price target, and the lowest target comes from Stifel-GMP with a C$5.50 price target.
Currently 4 analysts have revenue estimates for the second quarter. The mean between all 4 is $97.08 million; this number has been revised slightly higher from $87.08 million at the start of the year. The street high is $98.60 million while the lowest sits at $95.72 million.
Two analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 50.55%, with this number being revised slightly downwards from 51.70% at the start of the year. Street high goes to Stifel-GMP with a 53.50% estimate and the lowest sits at 47.60%.
Onto EBITDA estimates, there are currently 3 analysts who have second quarter EBITDA estimates. The mean is currently $26.82 million, with this number being higher than at the start of the year. Street high goes to Alliance Global with a $28.27 million EBITDA estimate and the lowest being a $26 million estimate.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
